Abbott secures CE mark for dual glucose-ketone sensor

ABBOTT PARK, Ill. - Abbott (NYSE:ABT) announced today it received CE Mark approval for Libre Duo and Libre Duo 10 Day, the first continuous monitoring systems to measure both glucose and ketone levels in people with diabetes, according to a press release statement. The $151 billion healthcare equipment manufacturer, trading at $86.67, continues to strengthen its position as a prominent player in the Healthcare Equipment & Supplies industry, according to InvestingPro analysis.

The sensors measure glucose and ketone levels every minute, designed to help detect rising ketones that can lead to diabetic ketoacidosis, a potentially life-threatening condition. The technology eliminates the need for traditional blood or urine ketone tests.

Libre Duo provides up to 15 days of wear for adults ages 18 and older, while Libre Duo 10 Day offers up to 10 days of wear for people ages 2 and older. Abbott plans to launch the systems in select European countries later this year.The product launch comes as Abbott’s stock trades near its 52-week low, currently sitting just 6% above that level. InvestingPro data indicates the stock appears undervalued based on Fair Value analysis, placing it among opportunities on the platform’s most undervalued stocks list. Investors can access comprehensive analysis through Abbott’s Pro Research Report, one of 1,400+ US equities covered with detailed insights.

The sensors integrate with Abbott’s Libre digital health ecosystem, allowing users to share glucose and ketone data with caregivers and healthcare providers. Abbott is working with pump manufacturers to enable compatibility with automated insulin delivery systems.

Diabetic ketoacidosis develops when the body lacks sufficient insulin and breaks down fat for energy, causing ketone levels to rise. The American Diabetes Association states that elevated ketones can escalate to DKA within hours and, if untreated, can lead to coma or death.

Research published in Diabetes Care shows hospital admissions for DKA increased approximately 55% over the past decade. A study of nearly 660,000 people in the United Kingdom presented at the 2026 Conference for Advanced Technologies & Treatments for Diabetes found DKA incidence in adults with Type 1 diabetes more than tripled over a 23-year period, while incidence among people with Type 2 diabetes increased sixfold.

The Centers for Disease Control and Prevention reports DKA accounts for approximately four times more hospitalizations than hypoglycemia in the United States.

The systems are not yet cleared or available for sale in the United States. Abbott’s Libre continuous glucose monitoring portfolio is currently used by more than 8 million people across over 60 countries.

In other recent news, Abbott Laboratories reported its first-quarter financial results, which revealed mixed outcomes. The company’s worldwide sales increased by 1%, aligning with consensus expectations, while adjusted earnings per share met Wall Street estimates. However, the revenue fell short of expectations on an organic growth basis, with notable underperformance in the medical device segment, particularly in diabetes sales. In response, Piper Sandler, Leerink Partners, and Bernstein SocGen all lowered their price targets for Abbott, citing the weak quarter and specific segment challenges. Despite the adjustments, Piper Sandler maintained an Overweight rating, while Bernstein SocGen kept an Outperform rating, and Leerink Partners held a Market Perform rating. Additionally, Abbott received FDA clearance and CE Mark for its Ultreon 3.0 Software, an AI-powered coronary imaging platform. The American Cancer Society also reaffirmed Abbott’s Cologuard and Cologuard Plus as preferred options for colorectal cancer screening. These developments reflect the company’s ongoing efforts to innovate and address market demands amidst financial challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.